Study of Ataluren in ≥2 to <5 Year-Old Male Participants With Duchenne Muscular Dystrophy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02819557|
Recruitment Status : Completed
First Posted : June 30, 2016
Results First Posted : August 28, 2020
Last Update Posted : August 28, 2020
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Duchenne Muscular Dystrophy||Drug: Ataluren||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||14 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase 2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Ataluren (PTC124®) in Patients Aged ≥2 to <5 Years Old With Nonsense Mutation Dystrophinopathy|
|Actual Study Start Date :||June 9, 2016|
|Actual Primary Completion Date :||February 9, 2018|
|Actual Study Completion Date :||February 9, 2018|
Participants will be administered ataluren orally at a dose of 10 milligrams/kilograms (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening (for a total of 40 mg/kg/day) for up to 52 weeks. Dose will be provided based upon the weight of each participant, which will be assessed every 12 weeks.
White to off-white powder for oral suspension.
- Number of Participants With Treatment Emergent Adverse Events (TEAEs), TEAEs Leading to Discontinuation, and Serious Adverse Events (SAEs) [ Time Frame: Baseline up to Week 56 ]A TEAE was any untoward medical occurrence or undesirable event that begins or worsens following administration of study drug, whether or not considered related to study drug by Investigator. An SAE was an adverse event (AE) resulting in any of the following outcomes or deemed significant for any other reason, death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying) or persistent or significant disability/incapacity not related to dystrophinopathy. An event was not reported as an SAE, if event was exclusively a relapse or expected change or progression of baseline dystrophinopathy. AEs included both SAEs and nonserious AEs. AEs classified according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 and coded using Medical Dictionary for Regulatory Activities. A summary of SAEs and all non-serious AEs, regardless of causality, is located in the Reported Adverse Events section.
- Number of Participants With a Clinically Meaningful Abnormal Clinical Laboratory (Biochemistry, Hematology, and Urinalysis) Parameter [ Time Frame: Baseline up to Week 56 ]Clinical laboratory results that were considered clinically meaningful were to be determined by the Investigator and Sponsor. Biochemistry parameters included sodium, potassium, chloride, bicarbonate, blood urea nitrogen, creatinine, magnesium, calcium, phosphorus, uric acid, glucose, total protein, albumin, bilirubin (total, direct, and indirect), aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transferase, creatine kinase, lactate dehydrogenase, alkaline phosphatase, total cholesterol, high-density lipoprotein, low-density lipoprotein, triglycerides, and cystatin C. Hematology parameters included white blood cell count with differential, hemoglobin, hematocrit, other red cell parameters, and platelet count. Urinalysis parameters included pH, specific gravity, glucose, ketones, blood, protein, urobilinogen, bilirubin, nitrite, and leukocyte esterase. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
- Number of Participants With a Clinically Meaningful Abnormal Electrocardiogram (ECG) Test Results [ Time Frame: Baseline up to Week 56 ]ECG results that were considered clinically meaningful were to be determined by the Investigator. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
- Number of Participants With a Dose-Limiting Toxicity as Measured by Hepatic and Renal Toxicity [ Time Frame: Baseline up to Week 56 ]
Dose-limiting toxicity was measured through clinical evaluations for potential hepatic and renal toxicities. The clinical evaluations included the following:
- Hepatic: The participant's medical history, hepatitis screening results, all clinical blood values (particularly serum bilirubin, gamma-glutamyl transferase [GGT], aspartate aminotransferase [AST], and alanine aminotransferase [ALT] values), and all concomitant medications were reviewed.
- Renal: The participant's medical history, all clinical blood and urine renal values, serum electrolytes, medications, and potential pre- or post-renal conditions were reviewed.
- Pharmacokinetics: Maximum Observed Plasma Concentration From Time Zero up to 6 Hours After the Morning Dose (Cmax0-6hr) [ Time Frame: 0 (predose), 1, 2, 4, and 6 (postdose) hours on Days 1 and 28 ]Ataluren concentrations in plasma were analyzed using a validated high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method.
- Pharmacokinetics: Time to Reach Maximum Observed Plasma Concentration From Time Zero up to 6 Hours After the Morning Dose (Tmax0-6hr) [ Time Frame: 0 (predose), 1, 2, 4, and 6 (postdose) hours on Days 1 and 28 ]Ataluren concentrations in plasma were analyzed using a validated HPLC-MS/MS method.
- Area Under the Plasma Concentration Time Curve From Time Zero up to 10 Hours After the Morning Dose (AUC0-10hr) [ Time Frame: 0 (predose), 1, 2, 4, 6, 8, and 10 (postdose) hours on Days 1 and 28 ]Ataluren concentrations in plasma were analyzed using a validated HPLC-MS/MS method. AUC0-10hr was measured using the linear trapezoidal rule during the ascending portion of the curve and the log-trapezoidal rule during the descending portion of the curve.
- Pharmacokinetics: Concentration at the End of the First (Morning) Dose Interval (Ctrough6hr) [ Time Frame: 0 (predose), 1, 2, 4, and 6 (postdose) hours on Days 1 and 28 ]Ataluren concentrations in plasma were analyzed using a validated HPLC-MS/MS method.
- Change From Baseline in Proximal Muscle Function as Assessed by Speed During TFTs [ Time Frame: Baseline, Week 28 and Week 52 ]TFTs included time to stand from supine position (rise to standing), time to run/walk 10 meters (m), and time to ascend/descend 4 stairs. A decrease from baseline reflects faster completion of the functional task and, thus, better muscle function. If the time taken to perform a test exceeded 30 seconds or if a participant could not perform the test due to disease progression (PD), a value of 30 seconds was used.
- Change From Baseline in Physical Function as Measured by the NSAA [ Time Frame: Baseline, Week 28 and Week 52 ]NSAA consists of 17 activities, including items assessing abilities necessary to remain functionally ambulant (that is, ability to rise from floor, to get from lying to sitting/sitting to standing, and that are known to progressively deteriorate); items that can be partly present in DMD early stages (that is, assessing head raise and standing on heels); and a number of activities such as hopping, jumping, and running. Since the boys were <5 years old, revised 16 point, 8-point, and 3-point scales were used over the 17 point scale. Scores for evaluations=0 (Unable to achieve independently), 1 (Modified method but achieved goal independent of physical assistance), or 2 (Normal, no obvious modification of activity). Maximum total score for the 16-point scale=32, 8-point scale=16, and 3-point scale=6. If an activity couldn't be performed due to PD/loss of ambulation, a score of 0 was assigned. Change from Baseline calculated by subtracting Baseline value from value at Week 28 and Week 52.
- Change From Baseline in Height of Participants at Weeks 4, 16, 28, 40, 52, and 56 [ Time Frame: Baseline, Weeks 4, 16, 28, 40, 52, and 56 ]
- Change From Baseline in Weight of Participants at Weeks 4, 16, 28, 40, 52, and 56 [ Time Frame: Baseline, Weeks 4, 16, 28, 40, 52, and 56 ]
- Change From Baseline in Body Mass Index of Participants at Weeks 4, 16, 28, 40, 52, and 56 [ Time Frame: Baseline, Weeks 4, 16, 28, 40, 52, and 56 ]Body mass index is an estimate of body fat based on body weight divided by height squared.
- Ataluren Palatability Characteristics as Determined by a Parent/Caregiver Questionnaire [ Time Frame: Baseline up to Week 28 ]
To assess palatability characteristics, participants/parents or guardians were asked to provide a response of "Strongly disagree", "Disagree", "Neither agree or disagree", "Agree", or "Strongly Agree" to the following 3 questions:
Question 1. "Is the medicine palatable?"
Question 2. "On the basis of reaction / facial expression of your child, do you think that the medication is pleasant?"
Question 3."You sometimes have problems in giving the medication to your child because he/she refuses to take it or throws it up?"
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||2 Years to 5 Years (Child)|
|Sexes Eligible for Study:||Male|
|Accepts Healthy Volunteers:||No|
- Males ≥2 to <5 years of age
- Body weight ≥12 kg
- Diagnosis of DMD
- Nonsense mutation in at least 1 allele of the dystrophin gene
- Participation in any other drug or device clinical investigation
- Ongoing use of prohibited concomitant medications
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02819557
|United States, Florida|
|Child Neuro NWF|
|Gulf Breeze, Florida, United States, 32561|
|United States, Illinois|
|Rush University Medical Center|
|Chicago, Illinois, United States, 60612|
|United States, Massachusetts|
|Children's Hospital Boston|
|Boston, Massachusetts, United States, 02115|
|United States, Ohio|
|Cincinnati Children's Hospital Medical Center|
|Cincinnati, Ohio, United States, 45229|
|United States, Texas|
|Children's Medical Center Dallas|
|Dallas, Texas, United States, 75390-8843|
|United States, Utah|
|University of Utah|
|Salt Lake City, Utah, United States, 84112|
|Study Director:||Francesco Bibbiani, MD||PTC Therapeutics|
Documents provided by PTC Therapeutics:
|Responsible Party:||PTC Therapeutics|
|Other Study ID Numbers:||
|First Posted:||June 30, 2016 Key Record Dates|
|Results First Posted:||August 28, 2020|
|Last Update Posted:||August 28, 2020|
|Last Verified:||August 2020|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Undecided|
Muscular Dystrophy, Duchenne
Muscular Disorders, Atrophic
Nervous System Diseases
Genetic Diseases, Inborn
Genetic Diseases, X-Linked